Key Takeaways SOLV posted Q4 adjusted EPS of $1.57 on $1.99B revenue, topping consensus estimates.SOLV saw organic growth across MedSurg, Dental, and HIS, led by infection prevention and restoratives.SOLV's gross margin fell 270 bps, while adjusted operating income declined 5.9% year over year.Solventum (SOLV) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.57, which beat the Zacks Consensus Estimate of $1.50 by 4.7%. The bottom line improved 11.3% year over year.GAAP EPS in the quarter ...

Industry Overview - The medical imaging industry is experiencing growth due to the increasing prevalence of chronic diseases, a rising geriatric population, and a focus on early and accurate diagnosis, with a projected CAGR of 6.65% through 2034 from $46.9 billion in 2026 [1] - Major companies in this sector, such as Hologic (HOLX) and GE HealthCare (GEHC), are attracting investor attention [1] Hologic (HOLX) Analysis - Hologic has developed multiple growth drivers through internal innovation and acquisitions, with Breast Health revenues increasing by 1.8% year over year in Q1 fiscal 2026, driven by Endomagnetics products [3] - GYN Surgical revenues rose by 8.7%, attributed to higher sales of MyoSure and Fluent devices, as well as the acquisition of Gynesonics [3] - However, Molecular Diagnostics revenues declined by 3.5% due to lower sales of COVID-19 tests and legacy assays, although growth in certain assays partially offset this decline [4] - Hologic ended Q1 with cash and cash equivalents of $2.17 billion and an adjusted net leverage ratio of 0.3X, and received FDA approval for its Aptima HPV Assay [5] - Hologic agreed to a buyout by Blackstone and TPG valued at up to $18.3 billion, offering shareholders $76 per share in cash, with a total potential value of $79 per share, indicating a 46% premium [6] GE HealthCare (GEHC) Analysis - GE HealthCare reported strong performance in Q4 2025, with double-digit organic revenue growth in Pharmaceutical Diagnostics and mid-single-digit growth in Imaging and Advanced Visualization Solutions, ending with a record backlog of $21.8 billion [7] - The company signed significant agreements, including a 7-year deal with the University of Rochester Medical Center, and plans to acquire Intelerad to enhance cloud-enabled imaging [8] - GEHC's D3 strategy focuses on using smart devices and digital tools for precision care, with new products contributing nearly 55% of revenues [10] - The company anticipates an increase in service agreement capture rates due to new innovations and has improved its business system, Heartbeat, leading to better sales and cash conversion [11] - Recent FDA clearances for new MR innovations and collaborations to advance AI in fetal ultrasound assessments further strengthen GEHC's position [12] Earnings Projections - The Zacks Consensus Estimate for Hologic's fiscal 2026 earnings indicates a 4.9% year-over-year growth to $4.47, with mixed estimate movements in the past 60 days [13] - For GE HealthCare, the earnings estimate for 2026 shows an 8.7% year-over-year growth to $4.99, with upward revisions in the last 60 days [14] Price Performance & Valuation - Hologic shares have increased by 0.7% over the past three months, while GE HealthCare shares have gained 4.2% [15] - Hologic trades at a forward price-to-sales (P/S) ratio of 3.87X, lower than its median, whereas GE HealthCare trades at a P/S of 1.76, in line with its median [16] Investment Outlook - Hologic's recent quarter performance was impacted by lower COVID testing and legacy STI test sales, with minimal upside potential from the buyout offer, suggesting current shareholders may consider exiting [19] - In contrast, GE HealthCare's strong segment performance and innovation strategy present it as a compelling investment opportunity, with bullish earnings projections [20]

Key Takeaways AVNS beat Q4 EPS and revenue estimates, but shares fell nearly 10% yesterday.Avanos Medical's SNS sales rose 8.7%, led by enteral feeding and neonate solutions growth.AVNS guides 2026 sales of $700-$720M and EPS of 90 cents to $1.10 amid tariff headwinds.Avanos Medical, Inc. (AVNS) reported fourth-quarter 2025 adjusted earnings per share (EPS) from continuing operations of 29 cents, down 32.6% year over year. However, the bottom line beat the Zacks Consensus Estimate of 24 cents by 20.8%.GAAP ...

Key Takeaways Inogen reported a narrower Q4 adjusted loss of 15 cents as revenues rose 2% year over year.International sales jumped 14.8%, offsetting a 5.1% drop in U.S. sales and a 4.5% fall in rentals.INGN guided 2026 revenues of $366M-$373M, about 6% growth at midpoint.Inogen, Inc. (INGN) incurred an adjusted loss per share of 15 cents for fourth-quarter 2025, which was narrower than the adjusted loss per share of 24 cents in the year-ago period and the Zacks Consensus Estimate of a loss of 36 cents per ...

Key Takeaways Stryker launched Synchfix EVT, a next-gen flexible fixation system for ankle syndesmotic injuries.SYK's device simplifies deployment, supports single-handed use and improves OR efficiency.Stryker's system is first approved for adolescents, expanding reach in ankle trauma care.Stryker (SYK) recently expanded its trauma portfolio with the launch of Synchfix EVT, a next-generation flexible syndesmotic fixation system to improve procedural efficiency and maintain effective ankle stabilization in p ...

Key Takeaways Hims & Hers reported strong quarterly revenue growth, driven by momentum in its Online channel.HIMS posted $617.8 million in Q4 revenue, driven by strong Online growth and 2.5 million subscribers.Hims & Hers' gross margin fell 487 bps to 71.9%, with 2026 revenue guided to $2.7 billion and $2.9 billionHims & Hers Health, Inc. (HIMS) came out with quarterly earnings per share (EPS) of 7 cents in fourth-quarter 2025, compared with the year-ago period’s EPS of 11 cents. However, the figure compare ...

GE HealthCare Technologies Inc. (NASDAQ:GEHC) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 5, Patrick Wood from Morgan Stanley lifted the price target on GE HealthCare Technologies Inc. (NASDAQ:GEHC) from $80 to $85, maintaining an Equal Weight rating. GE HealthCare Technologies Inc. (GEHC) Positioned to Capitalize on Strong Demand Backlog The analyst noted the company’s fourth-quarter results, which beat expectations and improved the stock’s risk-reward ...

Core Insights - A study by the American Cancer Society indicates that only about 20% of eligible individuals in the U.S. underwent lung cancer screening in 2024, suggesting a significant opportunity to improve early detection and potentially prevent approximately 62,110 lung cancer deaths over five years [1] Company Developments - Tempus AI, Inc. has partnered with Median Technologies to integrate the eyonis LCS solution into the Tempus Pixel platform, enhancing lung cancer screening capabilities with AI-based software [2] - The company received FDA 510(k) clearance for its Tempus ECG-Low EF software, which identifies patients with low left ventricular ejection fraction [3] - Tempus strengthened its imaging capabilities through the acquisition of Arterys in 2022, integrating AI-driven imaging tools into its ecosystem [4] Peer Updates - GE HealthCare launched the Voluson Performance series and acquired icometrix to enhance its AI-powered brain imaging analysis capabilities [5] - NANO-X IMAGING LTD received CE mark certification for its Nanox.ARC system, which generates tomographic images from a single sweep [6] Stock Performance - Tempus' shares have declined by 14.3% over the past year, while the industry has seen a 33.6% decline, contrasting with a 17.7% increase in the S&P 500 [7] - The company currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 6.45X, above the industry average of 5.66X [11] Earnings Estimates - Tempus AI's loss per share estimate for 2025 has remained unchanged over the past 30 days, with current estimates at -$0.59 for the current year and -$0.21 for the next year [12][13]

Core Insights - Integer Holdings Corporation (ITGR) reported adjusted earnings per share (EPS) of $1.76 for Q4 2025, a 23.1% increase year over year, exceeding the Zacks Consensus Estimate by 3.5% [1] - The company achieved revenues of $472.1 million in Q4 2025, reflecting a 5% year-over-year growth and surpassing the Zacks Consensus Estimate by 2% [2] - For the full year 2025, ITGR's revenues reached $1.85 billion, an 8% increase compared to 2024, with full-year EPS of $6.4, up 21% year over year [2] Revenue Breakdown - The Cardio and Vascular (C&V) segment generated revenues of $284.2 million in Q4 2025, an 11.3% increase year over year, driven by new product ramps and strong customer demand [5] - The Cardiac Rhythm Management & Neuromodulation (CRM&N) segment reported revenues of $167.3 million, down 1.9% year over year, due to a decline in Neuromodulation demand [6] - Revenues from the Other Markets segment totaled $20.5 million, down 13.2% year over year, attributed to the planned exit from the Portable Medical market [7] Margin and Expense Analysis - Gross profit for Q4 2025 was $124.8 million, a 6.8% increase year over year, with a gross margin of 26.4%, expanding by 50 basis points [8] - Selling, general and administrative expenses rose to $57.2 million, up 20.5% year over year, while total operating expenses increased by 15.2% to $68.8 million [10] - Adjusted operating profit was $83.3 million, reflecting a 9.6% increase from the prior year, with an adjusted operating margin of 17.6% [10] Financial Position - At the end of Q4 2025, ITGR had cash and cash equivalents of $17.2 million, down from $58.9 million at the end of Q3 2025, with total debt remaining flat at $1.19 billion [11] - Cumulative net cash flow from operating activities was $196.1 million, compared to $205.2 million a year ago [11] 2026 Guidance - For 2026, ITGR expects revenues between $1.826 billion and $1.876 billion, indicating a potential change of -1% to 1% from 2025 [12] - The company anticipates full-year adjusted EPS in the range of $6.29 to $6.78, reflecting a change of -2% to 6% from the previous year [12] Market Performance - Despite strong Q4 results, ITGR shares fell approximately 4% as investors focused on the 2026 guidance, which indicates slower adoption of new products [14] - Over the last six months, ITGR shares have declined by 22.7%, contrasting with a 4.9% decline in the industry and a 9.6% increase in the S&P 500 Index [15]

Core Insights - Artificial intelligence, particularly generative AI, is significantly transforming the MedTech industry, with companies like Tempus AI, Inc. leading the way in AI-driven healthcare solutions [1] Product Developments - Tempus launched its HRD-RNA algorithm in February 2026, a next-generation AI model designed to identify patients likely to respond to platinum-based chemotherapy or PARP inhibitors [2] - In January 2026, Tempus introduced Paige Predict, an AI-powered digital pathology application that analyzes whole slide images to assist in testing decisions [3] - Tempus received FDA clearance in July 2025 for its ECG-Low EF software, which uses AI to identify patients with low left ventricular ejection fraction [3] - The company also launched Notetaker in May 2025, an AI clinical assistant that records patient sessions to generate clinical notes for electronic health records [3] Industry Collaborations - GE HealthCare is collaborating with NVIDIA to utilize AI and high-performance computing to enhance patient comfort and reduce radiologist burnout [4] - Stryker's Mako SmartRobotics platform integrates AI to improve surgical accuracy in knee and hip procedures, with significant adoption and a recurring revenue model [5] Financial Performance - Tempus' stock has decreased by 21.9% over the past year, while the industry has seen a decline of 37.8%, contrasting with a 14.8% increase in the S&P 500 [6] - The company's current forward Price-to-Sales ratio is 6.63X, higher than the industry average of 5.66X, indicating an expensive valuation [9] Earnings Estimates - Tempus' loss per share estimates for 2025 have remained stable over the past 30 days, with projections of -0.59 for the current year and -0.21 for the next year [10][11]